

# Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2

Daniel J Jackson, MD, Arnaud Bourdin, MD, PhD<sup>b</sup>, Allison Blackorby, MSc<sup>c</sup>, Anna Leslie, MD<sup>d</sup>,  
Anna Vichiendilokkul, PharmD, MS<sup>e</sup>, Peter Howarth, DM, FRCP, FFPM (Hon)<sup>f</sup>, Natalia  
Karkoszka<sup>g,\*</sup>, MPharm, Shigeharu Fujieda, MD, PhD<sup>h</sup>, Marjolein Cornet, MD<sup>i</sup>

\*Affiliation at the time of the study

<sup>a</sup>Department of Pediatrics, Division of Allergy, Immunology & Rheumatology, University of  
Wisconsin School of Medicine and Public Health, Madison, WI, USA; <sup>b</sup>Département de  
Pneumologie et Addictologie, PhyMedExp, CHU Montpellier, Université de Montpellier,  
Montpellier, France; <sup>c</sup>Statistics, Respiratory Unit, GSK, Durham, NC, USA; <sup>d</sup>Clinical  
Development, Respiratory, Immunology and Inflammation Research Unit, GSK, London, UK;  
<sup>e</sup>Global Medical Affairs, GSK, Collegeville, PA, USA; <sup>f</sup>Global Medical Affairs, Respiratory  
Specialty Care, GSK, London, UK; <sup>g</sup>Specialty Safety, GSK, Warsaw, Poland; <sup>h</sup>Department of  
Otorhinolaryngology, Head & Neck Surgery, University of Fukui, Fukui, Japan; <sup>i</sup>Department of  
Otorhinolaryngology, Alrijne Hospital, Leiderdorp, Netherlands

**Corresponding author:** Daniel J Jackson, Department of Pediatrics, Division of Allergy,  
Immunology & Rheumatology, University of Wisconsin School of Medicine and Public Health,  
K4/936 CSC, 600 Highland Avenue, Madison, WI 53792, USA; Tel: +1 (608) 265-4003; Email:  
djj@medicine.wisc.edu

Table S1. Most common ( $\geq 3\%$ ) on-treatment AEs by time to onset (safety analysis population)

| Time to onset of AE, n (%) | Depemokimab<br>100 mg SC<br>(N=773) | Placebo<br>(N=517) |
|----------------------------|-------------------------------------|--------------------|
| <b>Nasopharyngitis</b>     |                                     |                    |
| 0–<26 weeks                | 68 (9)                              | 55 (11)            |
| 26–52+ weeks               | 43 (6)                              | 35 (7)             |
| <b>COVID-19</b>            |                                     |                    |
| 0–<26 weeks                | 76 (10)                             | 41 (8)             |
| 26–52+ weeks               | 36 (5)                              | 27 (5)             |
| <b>URTI</b>                |                                     |                    |
| 0–<26 weeks                | 47 (6)                              | 28 (5)             |
| 26–52+ weeks               | 29 (4)                              | 23 (4)             |
| <b>Headache</b>            |                                     |                    |
| 0–<26 weeks                | 30 (4)                              | 34 (7)             |
| 26–52+ weeks               | 19 (2)                              | 9 (2)              |
| <b>Bronchitis</b>          |                                     |                    |
| 0–<26 weeks                | 14 (2)                              | 11 (2)             |
| 26–52+ weeks               | 18 (2)                              | 10 (2)             |
| <b>Influenza</b>           |                                     |                    |
| 0–<26 weeks                | 15 (2)                              | 11 (2)             |
| 26–52+ weeks               | 15 (2)                              | 15 (3)             |
| <b>Allergic rhinitis</b>   |                                     |                    |
| 0–<26 weeks                | 24 (3)                              | 7 (1)              |
| 26–52+ weeks               | 10 (1)                              | 2 (<1)             |
| <b>Sinusitis</b>           |                                     |                    |
| 0–<26 weeks                | 19 (2)                              | 13 (3)             |
| 26–52+ weeks               | 10 (1)                              | 9 (2)              |
| <b>Arthralgia</b>          |                                     |                    |
| 0–<26 weeks                | 14 (2)                              | 8 (2)              |
| 26–52+ weeks               | 10 (1)                              | 8 (2)              |
| <b>Rhinitis</b>            |                                     |                    |
| 0–<26 weeks                | 14 (2)                              | 12 (2)             |
| 26–52+ weeks               | 12 (2)                              | 8 (2)              |
| <b>Cough</b>               |                                     |                    |
| 0–<26 weeks                | 15 (2)                              | 15 (3)             |
| 26–52+ weeks               | 9 (1)                               | 7 (1)              |
| <b>Hypertension</b>        |                                     |                    |
| 0–<26 weeks                | 12 (2)                              | 14 (3)             |
| 26–52+ weeks               | 9 (1)                               | 8 (2)              |
| <b>Back pain</b>           |                                     |                    |
| 0–<26 weeks                | 7 (1)                               | 16 (3)             |
| 26–52+ weeks               | 12 (2)                              | 8 (2)              |
| <b>Nasal polyps</b>        |                                     |                    |
| 0–<26 weeks                | 9 (1)                               | 12 (2)             |
| 26–52+ weeks               | 9 (1)                               | 10 (2)             |
| <b>Asthma</b>              |                                     |                    |
| 0–<26 weeks                | 10 (1)                              | 16 (3)             |
| 26–52+ weeks               | 9 (1)                               | 8 (2)              |

|                         |       |        |
|-------------------------|-------|--------|
| <b>Nasal congestion</b> |       |        |
| 0–<26 weeks             | 5 (1) | 10 (2) |
| 26–52+ weeks            | 6 (1) | 7 (1)  |

AE, adverse event; SC, subcutaneous; URTI, upper respiratory tract infection.


Note: Time to onset refers to the patient's first AE occurrence.

*Table S2. Summary of on-treatment treatment-related AEs occurring in  $\geq 2$  patients in either treatment group (safety analysis population)*

| <b>Treatment-related AE, n (%)</b> | <b>Depemokimab 100 mg SC<br/>(N=773)</b> | <b>Placebo<br/>(N=517)</b> |
|------------------------------------|------------------------------------------|----------------------------|
| <b>Any event</b>                   | 36 (5)                                   | 15 (3)                     |
| Headache                           | 5 (<1)                                   | 1 (<1)                     |
| Injection-site reaction            | 5 (<1)                                   | 0                          |
| Fatigue                            | 3 (<1)                                   | 0                          |
| ALT increased                      | 2 (<1)                                   | 1 (<1)                     |
| Leukopenia                         | 2 (<1)                                   | 0                          |
| Injection-site pain                | 0                                        | 2 (<1)                     |
| Pain in extremity                  | 0                                        | 2 (<1)                     |

AE, adverse event; ALT, alanine aminotransferase; SC, subcutaneous.

Figure S1. Patient disposition (full analysis set)



\*In SWIFT-2, one patient who was assigned to the depemokimab group received placebo for the duration of the study and was therefore included in the placebo group for safety analyses in line with the predefined analysis sets; <sup>‡</sup>Limited to the five most commonly reported reasons for study withdrawal

(according to the depemokimab group); <sup>‡</sup>Lack of efficacy was only a reason for study withdrawal in the SWIFT-1/-2 studies; <sup>§</sup>Patients reached protocol-defined stopping criteria due to pregnancy.

AE, adverse event; SC, subcutaneous; SoC, standard of care.